Vol. 19 No. 3 (2020): Mapana Journal of Sciences
Research Articles

Molecular Docking Study of Several Antiviral Drugs to Defeat Covid-19

PDF
  • Jasdev S. Tuteja,
  • Priti Patidar,
  • Shilpa E. Mathew,
  • Anil Prajapati
Jasdev S. Tuteja
Devi Ahilya Vishwavidyalaya
Bio
Priti Patidar
Devi Ahilya Vishwavidyalaya
Bio
Shilpa E. Mathew
Devi Ahilya Vishwavidyalaya
Bio
Anil Prajapati
Devi Ahilya Vishwavidyalaya
Bio
DOI: https://doi.org/10.12723/mjs.54.4

Published 2020-07-01

Keywords

  • Molecular Docking,
  • Corona Virus,
  • PDB,
  • Molegro Virtual Docker

Copyright (c) 2020

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Abstract

Corona virus is one of the significant pathogens that destructs the human respiratory functioning. Deaths and casualties caused by coronaviruses (CoVs) include the severe acute respiratory syndrome (SARS)-CoV and the Middle East respiratory syndrome (MERS)-CoV. The aim of the work was to compare several antiviral drugs and find out which is the most active drug that might be used in treatment for COVID -19. In this study Molecular Docking approach was used to determine the binding affinities of 62 antiviral molecules. The study was carried out using Molegro Virtual Docker 6.0 with PDB 2GTB procured from RCSB Protein Data Bank. Simeprevir and Telaprevir were discovered to be most potent having high MolDock and Rerank scores of -225.158, -78.4383 and -209.467, -136.155 respectively. Further studies may be conducted to design more potent analogue and defeat COVID-19.

PDF

References

  1. Assiri A., Al-Tawfiq J.A., Al-Rabeeah A.A., Al-Rabiah F.A., Al-Hajjar S., Al-Barrak A.,A. Flemban H., Al-Nassir W.N., Balkhy H.H., Al-Hakeem R.F. and Makhdoom H.Q.,Epidemiological, demographic, and clinical characteristics of 47 cases of MiddleEast respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study, Lancet Infect. Dis., (13), 752 (2013)
  2. Bassetti M., Vena A., Giacobbe D. Roberto, The Novel Chinese Coronavirus (2019-nCoV) Infections: challenges for fighting the storm, Eur. J. Clin. Invest., 13209(2020)
  3. Bogoch, A. Watts, A. Thomas-Bachli, C. Huber, M.U.G. Kraemer, K. Khan, Pneumonia of unknown etiology in wuhan, China: potential for international spread via commercial air travel, J. Trav. Med. (2020)
  4. Carlos W.G., Cruz C.S. Dela, Cao B., Pasnick S., Jamil S., Novel wuhan (2019-nCoV) coronavirus, Am. J. Respir. Crit. Care Med., 201 (4), 7(2020)
  5. Chaudhuri, S., Symons, J.A. and Deval, J.,Innovation and trends in the development and approval of antiviral medicines: 1987–2017 and beyond. Antiviral Res., 155,76 (2018)
  6. Chen H., Guo J., Wang C., Luo F., Yu X., Zhang W., Liao, J., Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet, 395(10226),809 (2020)
  7. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Yu T., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet395 (10223), 507 (2020)
  8. Cui J., Li F., Shi Z.L., Origin and evolution of pathogenic coronaviruses, Nat. Rev. Microbiol. 17,181 (2019)
  9. De Clercq, E. and Li, G., Approved antiviral drugs over the past 50 years. Clinical microbiology Rev., 29(3), 695(2016)
  10. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang, L., Fan, G., Xu, J., Gu, X. and Cheng, Z., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395 (10223), 497(2020)
  11. Hui D.S., IA E., Madani T.A., Ntoumi F., Kock R., Dar O., The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China, Int. J. Infect. Dis., (9),264 (2020)
  12. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
  13. Jaimes J.A., Millet J.K., Stout A.E., Andre N.M., Whittaker G.R., A tale of two viruses: the distinct spike glycoproteins of feline coronaviruses, Viruses(12), 365 (2020)
  14. Lee N., Hui D., Wu A., Chan P., Cameron P., Joynt G.M., Ahuja A., Yung MY., Leung CB., To KF., Lui SF., A major outbreak of severe acute respiratory syndrome in Hong Kong, N. Engl. J. Med.348, 1986 (2003)
  15. Lei J., Li J., Li X., Qi X., CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia, Radiology, (200236), (2020)
  16. Lu H., Drug treatment options for the 2019-new coronavirus (2019-nCoV), Bio sci. Trends., (2020)
  17. Lu.H, Stratton C.W., Tang Y.W., Outbreak of pneumonia of unknown etiology in wuhan China: the mystery and the miracle, J. Med. Virol. 92 (4), 401(2020)
  18. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., Bi Y., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, 395 (10224),565 (2020)
  19. Nishiura H., Jung S.M., Linton N.M., Kinoshita R., Yang Y., Hayashi K., Kobayashi T, Yuan B, Akhmetzhanov AR, The extent of transmission of novel coronavirus in wuhan, China,J. Clin. Med., (9), (2020)
  20. Phan L.T, Nguyen T.V., Luong Q.C., Nguyen T.V., Nguyen H.T., Le H.Q., Nguyen T.T., Cao T.M. and Pham Q.D.,Importation and human-to-human transmission of a novel coronavirus in Vietnam, N. Engl. J. Med.., (2020)
  21. Ren L.L., Wang Y.M., Wu Z.Q., Xiang Z.C., Guo L., Xu T., Jiang Y.Z., Xiong Y., Li Y.J. Li X.W. and Li H., Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study, Chinese Med Journal, (2020)
  22. Rothan, H.A. and Byrareddy, S.N., The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of autoimmunity,102433, (2020)
  23. Samant L, Javle V., Comparative Docking analysis of rational drugs against COVID-19 Main Protease.ChemRxiv., (2020)
  24. Toit Du.A, Outbreak of a novel coronavirus, Nat. Rev. Microbiol. 18 (123),(2020)
  25. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z, Hu Z, Zhong W, Xiao G, Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in Vitro, Cell research, (2020)
  26. Wang W., Tang J., Wei F., Updated understanding of the outbreak of 2019 novel coron6avirus (2019-nCoV) in Wuhan, China, J. Med. Virol. 92 (4),44(2020)
  27. Wan Y., Shang J., Graham R., Baric R.S., Li F., Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS, J. Virol., (2020)
  28. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X, Huang B, Shi W, Lu R, Niu P, A novel coronavirus from patients with pneumonia in China, N. Engl. J. Med.382,727 (2019)